Piramal Healthcare, (BSE - 500302, NSE - PIRHEALTH) is India's second largest Pharmaceutical Healthcare company with a presence in the cardio-vascular segment, the antibiotics and respiratory segments, pain management, neuro-psychiatry and anti-diabetics segments and biotechnology. It is based in Mumbai. Nicholas Piramal India Ltd. is now known as Piramal Healthcare Ltd.
Dubbed as the second largest deal in Indian pharmaceuticals market, Abbott Laboratories has acquired the chemical solution business from Piramal Healthcare Ltd for around $3.2 billion. The reason behind the venture being India, the fastest developing country in pharmaceuticals.
NPIL's brands in the pharma business are Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these bring in 67% of the business, while its secondary brands which include Paraxin, Flagyl and Omnatax contribute around 24% of its revenues.
NPIL came into existence in 1988 when it acquired Nicholas Laboratories from Sara Lee and in the last 15 years grown primarily on acquisitions, mergers and alliances. Some of NPIL's acquisitions include the Indian operations of Roche Products Ltd., Boehringer Mannheim India Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone Poulenc India Ltd., ICI India Ltd.'s Pharma Division and Aventis' Research facilities.
NPIL has joint ventures and alliances with F. Hoffmann-La Roche Ltd., Switzerland; Allergan Inc., USA; UK; Gilead Sciences, USA; Cheissi, Italy; and IVAX Corp; UK.
NPIL's has a 2,700-strong field force. NPIL, together with its JVs, has 16 strong brands in the Indian Pharma Industry; manufacturing plants - NPIL has plants in Hyderabad and Pithampur.
With the acquisition of Pfizer's Morpeth manufacturing site in the UK, Nicholas Piramal through its wholly owned subsidiary NPIL Pharmaceuticals Limited is a custom manufacturing organization.
NPIL plans to take advantage of the opportunities that will emerge in the bulk actives and intermediates market for contract manufacturing at attractive price points of both on patent and off patent drugs for the regulated markets of Europe, US and Japan. NPIL major investments in R&D which focus on formulations development, new chemical entity research, clinical research from laboratories in India and abroad. The results till now however have not been very encouraging.
Nicholas Piramal India Ltd has announced with reference to the earlier announcement dated January 22, 2008 regarding fixing of the Record Date for the purpose of determining entitlement of the shareholders of the Company to receive equity shares of "NPIL Research and Development Ltd" (NPIL) in the ratio of 1:10 pursuant to the Scheme, that the name of "NPIL Research and Development Ltd" has been changed to "Piramal Life Sciences Ltd". A certified true copy of Fresh Certificate of Incorporation Consequent upon change of Name issued by the Ministry of Corporate Affairs.
NPIL is the flagship company of the Rs. 25,000 million (US $ 500 million) Piramal Enterprises (PEL). The Group is headed by Ajay Piramal, who is also the Chairman of NPIL.